Therapeutic
Cancer Vaccine
AST-021p
HSP90 Vaccine (Peptide)- Overview
- • Product Type: Peptide-based therapeutic cancer vaccine
- • Mode of Action: Induction of Th1-cell immunity against HSP90
- • A Phase 1 study is underway in Korea to evaluate the safety and tolerability of AST-021p in advanced solid cancer (NCT04864418)
- • Also known as CornerStone-002 Trial
AST-023
HSP90 Vaccine (DNA)- Overview
- • Product Type: Plasmid-based therapeutic cancer vaccine
- • Mode of Action: Induction of Th1-cell immunity against HSP90
AST-301 (HER2 1+/2+ Breast Cancer)
HER2-hICD Vaccine (DNA)- Overview
- • Product Type: Plasmid DNA based therapeutic cancer vaccine
- • Mode of Action: Induction of Th1-cell immunity against HER2
- • A Phase 2 study is underway in the U.S. and Taiwan to assess the safety and efficacy of AST-301 in combination with standard adjuvant therapies in breast cancer (NCT05163223)
- • Also known as CornerStone-001 Trial
AST-301 (Gastric Cancer)
HER2-hICD Vaccine (DNA)- Overview
- • Product Type: Plasmid DNA based therapeutic cancer vaccine
- • Mode of Action: Induction of Th1-cell immunity against HER2
- • A Phase 2 study is underway in Taiwan to evaluate the efficacy and safety of therapeutic cancer vaccine (AST-301, pNGVL3-hICD) in patients with gastric cancer
- • Also known as CornerStone-003 Trial
AST-302
Multiple Antigen Vaccine- Overview
- • Product Type: Plasmid DNA based therapeutic cancer vaccine
- • Mode of Action: Induction of Th1-cell immunity against multiple antigens commonly expressed in breast cancer
- • The result of Phase 1 study has been presented at San Antonio Breast Cancer Symposium (NCT02780401)
- • A Phase 2 study of the vaccine, given in the neoadjuvant setting to patients with HER2 positive breast cancer, is ongoing (NCT04329065)
AST-201
IGFBP2 Vaccine (DNA)- Overview
- • Product type: Plasmid DNA based therapeutic cancer vaccine
- • Mode of action: Induction of Th1-cell immunity against IGFBP-2
- • Study Objective: To evaluate the clinical efficacy of AST-201 versus placebo as measured by progression-free survival (PFS)
- • Also known as CornerStone-004 Trial
AST-202
Multiple Antigen Vaccine- Overview
- • Product Type: Plasmid DNA based therapeutic cancer vaccine
- • Mode of Action: Induction of Th1-cell immunity against multiple antigens related with EMT
AST-065
TLR-2/3 Agonist (as immune adjuvant)- Overview
- • Product Type: TLR2/3 agonist based immune adjuvant
- • Mode of Action: Augmentation of the effect of immune therapy including vaccine
AST-07X
TROP2 target peptide-based therapeutic cancer vaccine- Overview
- Not disclosed
AST-09X
Not disclosed- Overview
- Not disclosed
AST-10X
Not disclosed- Overview
- Not disclosed
AST-11X
Not disclosed- Overview
- Not disclosed
AST-12X
Not disclosed- Overview
- Not disclosed
